Souza Maria Ivaldete Siqueira de, Crispim Myuki Alfaia Esashika, Fraiji Nelson Abrahim, Silva-Junior Alexander Leonardo, Stefani Mariane Martins de Araújo
Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil; Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, GO, Brazil.
Braz J Infect Dis. 2024 Jul-Aug;28(4):103848. doi: 10.1016/j.bjid.2024.103848. Epub 2024 Jul 17.
The Amazonas state/AM and Manaus rank among the highest AIDS detection rates in Brazil. High proportion of HIV infected blood donors and transmission clusters of multidrug antiretroviral/ARV resistant viruses were described in HEMOAM blood donors, a main Amazonas public blood bank. Recent and long-term infections among previously genotyped donors are reported.
METHODS/MATERIALS: The recency immunoassay Lag Avidity EIA (Maxim, USA) was employed. Clinical/CD4/viral load medical file data of the main local HIV management center (FMT-HVD) and ARV treatment/ART data were reviewed.
Among 142 HIV-blood donors, chronic infection predominated (n = 87; 61.3 %), 79 based on LAg EIA and 8 undisclosed HIV identified in FMT-HVD records, mostly young adult, single males, 4 repeat donors, all ART-naive. Recent infections represented 30.3 % (n = 43), 39 identified by LAg EIA and 4 immunologic windows (antibody negative/NAT/RNA positive). The overall profile of recent and long-term infections was similar, including moderate rate of transmitted drug resistance/TDR, however with multiple resistance mutations to more than one ARV-class, suggesting ART/failure.
Recent/acute and undisclosed/long-term HIV infections represent blood safety alerts suggesting test-seeking behavior of at-risk populations. Early ART use in Brazil, can turn HIV diagnosis more challenging representing a blood transfusion risk in the highly endemic Brazilian Amazon.
亚马孙州/AM及玛瑙斯市在巴西艾滋病检测率中位居前列。在亚马孙州主要的公共血库HEMOAM的献血者中,发现了高比例的HIV感染献血者以及多药抗逆转录病毒/ARV耐药病毒的传播集群。报告了先前基因分型的献血者中的近期感染和长期感染情况。
方法/材料:采用了近期免疫测定法Lag Avidity EIA(美国Maxim公司)。回顾了当地主要HIV管理中心(FMT - HVD)的临床/CD4/病毒载量医疗档案数据以及抗逆转录病毒治疗/ART数据。
在142名HIV献血者中,慢性感染占主导(n = 87;61.3%),其中79例基于LAg EIA检测,8例在FMT - HVD记录中未披露的HIV感染者,大多为年轻成年单身男性,4名重复献血者,均未接受过抗逆转录病毒治疗。近期感染占30.3%(n = 43),其中39例通过LAg EIA检测,4例处于免疫窗口期(抗体阴性/NAT/RNA阳性)。近期感染和长期感染的总体情况相似,包括中等比例的传播耐药性/TDR,然而存在对不止一种ARV类药物的多重耐药突变,提示抗逆转录病毒治疗失败。
近期/急性和未披露/长期的HIV感染代表血液安全警报,提示高危人群的检测寻求行为。在巴西早期使用抗逆转录病毒治疗可能使HIV诊断更具挑战性,这在巴西艾滋病高发的亚马孙地区代表着输血风险。